Survodutide
Survodutide is a dual glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) agonist designed to mimic the effects of oxyntomodulin. Currently being evaluated in clinical trials as a potential treatment for obesity and obesity-related metabolic disorders, including metabolic dysfunction-associated steatohepatitis (MASH).
Survodutide
Sale!
Survodutide is a dual glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) agonist designed to mimic the effects of oxyntomodulin. Currently being evaluated in clinical trials as a potential treatment for obesity and obesity-related metabolic disorders, including metabolic dysfunction-associated steatohepatitis (MASH).
$150.00
Buy more, save more!
-
Save 2%
Buy 3, get $2.50 off each
$150.00Per item: $147.50Total price: $442.50 -
Save 3%
Buy 5, get $3.75 off each
$150.00Per item: $146.25Total price: $731.25 -
Save 5%
Buy 10, get $7.50 off each
$150.00Per item: $142.50Total price: $1,425.00
$198.00$150.00
99+% PURITY
All peptides are third-party lab tested.
SECURE PAYMENT
Your payments are secure with our private security network.
FREE SHIPPING
for orders over $250
Description
Additional information
Reviews (0)
Survodutide is a dual glucagon receptor (GCGR) and glucagon-like peptide-1 (GLP-1) receptor agonist peptide under investigation for metabolic disorders. It provides a high-quality research material for preclinical studies of obesity, glucose metabolism, and metabolic disease. By activating both the GLP-1 and glucagon receptors, Survodutide is being investigated for its ability to improve glucose regulation, reduce food intake by increasing satiety, promote weight loss, and increase energy expenditure. Phase 2 trials have reported improvements in histological markers of metabolic dysfunction-associated steatohepatitis (MASH), reductions in liver fat content, and significant weight loss in participants with obesity, with or without type 2 diabetes.
There are no reviews yet.